An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma.
暂无分享,去创建一个
Yingyao Zhou | L. Sapinoso | H. Frierson | G. Hampton | T. Bauknecht | W. Jonat | I. Meinhold-Heerlein | E. Stickeler | J. Sehouli | D. Könsgen | D. Bauerschlag | N. Arnold | J. Pfisterer | F. Hilpert | K. Bräutigam | C. von Kaisenberg | K. Ching
[1] M. Milivojevic,et al. SERUM PROTEIN MARKERS FOR EARLY DETECTION OF OVARIAN CANCER , 2009 .
[2] D. Fishman,et al. Matrilysin (MMP‐7) promotes invasion of ovarian cancer cells by activation of progelatinase , 2005, International journal of cancer.
[3] Jalid Sehouli,et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential , 2005, Oncogene.
[4] A. Arakawa,et al. Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis. , 2005, Gynecologic oncology.
[5] A. Harris,et al. Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. , 2004, Gynecologic oncology.
[6] Anne-Marie Mes-Masson,et al. Signature of a silent killer: expression profiling in epithelial ovarian cancer , 2004, Expert review of molecular diagnostics.
[7] Michèl Schummer,et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. , 2003, Cancer research.
[8] R. Bast,et al. Status of tumor markers in ovarian cancer screening. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Welsh,et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[10] Ignace Vergote,et al. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. , 2003, Cancer research.
[11] George M Yousef,et al. Human tissue kallikreins: a family of new cancer biomarkers. , 2002, Clinical chemistry.
[12] R. Berkowitz,et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. , 2002, JAMA.
[13] R. Berkowitz,et al. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. , 2001, Journal of the National Cancer Institute.
[14] J. Welsh,et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. , 2001, Cancer research.
[15] S. Memarzadeh,et al. Advances in the management of epithelial ovarian cancer. , 2001, The Journal of reproductive medicine.
[16] D. Lockhart,et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[17] J. Berek,et al. Ovarian cancer: epidemiology, biology, and prognostic factors. , 2000, Seminars in surgical oncology.
[18] P. Kenemans,et al. CA 125: fundamental and clinical aspects. , 1999, Seminars in cancer biology.
[19] Yan Yan,et al. The Matrix Metalloprotease Pump-1 (MMP-7, Matrilysin): A Candidate Marker/Target for Ovarian Cancer Detection and Treatment , 1999, Tumor Biology.
[20] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[21] S. Barnhill,et al. CA 125: The past and the Future , 1998, The International journal of biological markers.
[22] L. Wodicka,et al. Genome-wide expression monitoring in Saccharomyces cerevisiae , 1997, Nature Biotechnology.
[23] R. Berkowitz,et al. Osteopontin as an Adjunct to CA 125 in Detecting Recurrent Ovarian Cancer , 2004 .
[24] D. Lockhart,et al. Expression monitoring by hybridization to high-density oligonucleotide arrays , 1996, Nature Biotechnology.